Economic Impact of Candida Colonization and Candida Infection in the Critically Ill Patient

  • P. M. Olaechea
  • M. Palomar
  • C. León-Gil
  • F. Álvarez-Lerma
  • R. Jordá
  • J. Nolla-Salas
  • M. A. León-Regidor
  • the EPCAN Study Group
Article

Abstract

The objective of the study presented here was to assess the economic impact of Candida colonization and Candida infection in critically ill patients admitted to intensive care units (ICUs). For this purpose, a prospective, cohort, observational, and multicenter study was designed. A total of 1,765 patients over the age of 18 years who were admitted for at least 7 days to 73 medical-surgical ICUs in 70 Spanish hospitals between May 1998 and January 1999 were studied. From day 7 of ICU admission to ICU discharge, samples of tracheal aspirates, pharyngeal exudates, gastric aspirates and urine were collected every week for culture. Prolonged length of stay was associated with severity of illness, Candida colonization or infection, infection by other fungi, antifungal therapy, treatment with more than one antifungal agent, and toxicity associated with this therapy. Compared to non-colonized, non-infected patients (n=720), patients with Candida colonization (n=880) had an extended ICU stay of 6.2 days (OR, 1.69; 95%CI, 1.53–1.87; P<0.001) and an extended hospital stay of 8.6 days (OR, 1.27; 95%CI, 1.16–1.40; P<0.001). The corresponding figures for patients with Candida infection (n=105) were 12.7 days for ICU stay (OR, 2.13; 95%CI, 1.72–2.64; P<0.001) and 15.5 days for hospital stay (OR, 1.23; 95%CI, 0.99–1.52; P=0.060). Candida colonization resulted in an additional 8,000 EUR in direct costs and Candida infection almost 16,000 EUR. Both Candida colonization and Candida infection had an important economic impact in terms of cost increases due to longer stays in both the ICU and in the hospital.

References

  1. 1.
    Jarvis WR (1996) Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 17:552–557PubMedGoogle Scholar
  2. 2.
    Baker JJ, Lambert RL, Poulos KM, Feldman JI (2000) Managing the cost of care: a predictive study to identify critical care patients at risk for nosocomial pneumonia. J Health Care Finance 26:73–82PubMedGoogle Scholar
  3. 3.
    Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ (1999) The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 17:725–730Google Scholar
  4. 4.
    Peña C, Pujol M, Pallarés R, Corbella X, Vidal T, Tortras N, Ariza J, Gudiol F (1996) Estimation of costs attributable to nosocomial infection: prolongation of hospitalization and calculation of alternative costs [Article in Spanish]. Med Clin (Barc) 106:441–444Google Scholar
  5. 5.
    Pfaller MA (1995) Epidemiology of candidiasis. J Hosp Infect 30 (Suppl):329–338PubMedGoogle Scholar
  6. 6.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751–758PubMedGoogle Scholar
  7. 7.
    Trilla A (1994) Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 20 (Suppl 3):1–4Google Scholar
  8. 8.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedGoogle Scholar
  9. 9.
    Center for Diseases Control (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescent and adult. MMWR 41 (RR-17):1–19Google Scholar
  10. 10.
    Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693PubMedGoogle Scholar
  11. 11.
    Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, and the L Amph/ABLC Collaborative Study Group (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163CrossRefGoogle Scholar
  12. 12.
    Goldman L, Hashimoto B, Cook EF, Localzo A (1981) Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 64:1227–1234PubMedGoogle Scholar
  13. 13.
    Nolla-Sala J, Sitges-Serra A, León C, de la Torre MV, Sancho H (1996) Candida endophthalmitis in non-neutropenic critically ill patients. Eur J Clin Microbiol Infect Dis 15:503–506PubMedGoogle Scholar
  14. 14.
    Wakefield DS, Helms CM, Massanari RM, Mori M, Pfaller M (1988) Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections. Am J Infect Control 16:185–192PubMedGoogle Scholar
  15. 15.
    Olaechea PM, Ulibarrena MA, Alvarez-Lerma F, Insausti J, Palomar M, De la Cal MA, ENVIN-UCI Study Group (2003) Factors related to hospital stay among patients with nosocomial infection acquired in the intensive care unit. Infect Control Hosp Epidemiol 24:207–213PubMedGoogle Scholar
  16. 16.
    Girou E, Stephan F, Novara A, Safar M, Fagon JY (1998) Risk factors and outcome of nosocomial infections: results of a matched case-control study of ICU patients. Am J Respir Crit Care Med 157:1151–1158PubMedGoogle Scholar
  17. 17.
    Asensio Vegas A, Monge Jodra V, Lizán García M (1993) Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization. Eur J Epidemiol 9:504–510PubMedGoogle Scholar
  18. 18.
    Rentz AM, Halpern MT, Bowden R (1998) The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27:781–788PubMedGoogle Scholar
  19. 19.
    Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645PubMedGoogle Scholar
  20. 20.
    Petri MG, König J, Moecke HP, Gramm HJ, Barkow H, Kujath P, Dennhart R, Schäfer H, Meyer N, Kalmar P, Thülig P, Müller J, Lode H, Paul-Ehrlich Society for Chemotherapy Division of Mycology and Pneumonia Research (1997) Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 23:317–325PubMedGoogle Scholar
  21. 21.
    Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, Tong KB (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18:2476–2483PubMedGoogle Scholar
  22. 22.
    Cannon JP, Garey KW, Danziger LH (2001) A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 21:1107–1114PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • P. M. Olaechea
    • 1
  • M. Palomar
    • 2
  • C. León-Gil
    • 3
  • F. Álvarez-Lerma
    • 4
  • R. Jordá
    • 5
  • J. Nolla-Salas
    • 4
  • M. A. León-Regidor
    • 6
  • the EPCAN Study Group
  1. 1.Emergency Service and Intensive Care MedicineHospital de GaldakaoGaldakaoSpain
  2. 2.Service of Intensive Care MedicineHospital Vall d’HebronBarcelonaSpain
  3. 3.Service of Intensive MedicineHospital de ValmeSevillaSpain
  4. 4.Service of Intensive Care MedicineHospital Universitari del MarBarcelonaSpain
  5. 5.Service of Intensive Care MedicineHospital Son DuretaPalma de MallorcaSpain
  6. 6.Intensive Care UnitHospital de BarcelonaBarcelonaSpain

Personalised recommendations